Fig. 1

PAQR8 gain in human and mouse tumors is associated with recurrence and disease progression. A Patients in the METAMORPH cohort, depicting receptor status in primary (Pri) and recurrent (Rec) tumors, treatments received, and mutation or copy number status. B Cox proportional hazards regression analysis of survival after clinical progression following recurrence for patients whose recurrent tumors had activating mutations in ESR1 (n = 7), mutations in PGR (n = 2), gain of PAQR8 (n = 26), or patients with tumors lacking these three alterations (WT, n = 13). C–F Cox proportional hazards regression analysis of different survival outcomes with respect to PAQR8 gain in primary tumors within the TCGA breast cancer dataset. C Time to recurrence in patients who experienced recurrence across all subtypes controlling for HR/HER2 status (n = 49 WT, 11 PAQR8 gain). Overall survival (n = 378 WT, 72 PAQR8 gain) (D), recurrence-free survival (n = 354 WT, 66 PAQR8 gain) (E), and survival after recurrence (n = 28 WT, 7 PAQR8 gain) (F) in HR +/HER2- patients. G Frequencies of CN gain (red) and CN loss (blue) of PAQR8/Paqr8 in primary and recurrent tumors in humans (left; n = 28 Pri, 66 Rec) and mice (right; n = 159 Pri, 169 Rec). Low-level CNAs (gain and loss) and high-level CNAs (amplification and deletion) are shown as hashed and solid bars, respectively. P values indicate one-sided Fisher’s exact tests. H Paqr8 RNA expression in primary (n = 48) and recurrent (n = 46) tumors across five different GEM models. P values indicate one-sided Wilcoxon rank-sum tests. Median fold-change (FC)